Role of inflammatory markers in corona virus disease (COVID-19) patients: A review.


Journal

Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 9 7 2020
medline: 29 8 2020
entrez: 9 7 2020
Statut: ppublish

Résumé

In late 2019, a novel virus called SARS-CoV-2, expanded globally from Wuhan, China and was declared a pandemic on 11 March 2020 by the WHO. The mechanism of virus entry inside the host cell depends upon the cellular proteases including cathepsins, HAT, and TMPRSS2, which splits up the spike protein and causes further penetration. MERS coronavirus uses DPP4, while coronavirus HCoV-NL63 and SARS-CoV and SARS-CoV-2 employ ACE-2 as the key receptor. Cytokine storm syndrome was analyzed in critically ill nCOVID-19 patients and it is presented with high inflammatory mediators, systemic inflammation, and multiple organ failure. Among various inflammatory mediators, the level of interleukins (IL-2, IL-7, IL-10), G-CSF, MIP1A, MCP1, and TNF-α was reported to be higher in critically ill patients. Understanding this molecular mechanism of ILs, T cells, and dendritic cells will be helpful to design immunotherapy and novel drugs for the treatment of nCOVID-19 infection.

Identifiants

pubmed: 32635752
doi: 10.1177/1535370220939477
pmc: PMC7441343
doi:

Substances chimiques

Biomarkers 0
Cytokines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1368-1375

Références

J Med Virol. 2005 Feb;75(2):185-94
pubmed: 15602737
Surg Infect (Larchmt). 2005;6 Suppl 1:S41-6
pubmed: 19284357
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Adv Protein Chem. 2005;70:247-99
pubmed: 15837518
J Immunol. 2011 Feb 1;186(3):1333-7
pubmed: 21191067
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Blood. 2007 Mar 1;109(5):1971-4
pubmed: 17082318
FEMS Microbiol Rev. 1993 Nov;12(4):325-48
pubmed: 8268005
Semin Immunopathol. 2017 Jul;39(5):541-550
pubmed: 28555383
Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7
pubmed: 15657466
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Semin Immunopathol. 2012 Jan;34(1):43-62
pubmed: 22037947
Immunity. 2005 Apr;22(4):507-17
pubmed: 15845454
Eur Respir J. 2009 May;33(5):1165-85
pubmed: 19407051
Infect Immun. 1984 May;44(2):320-5
pubmed: 6425220
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
N Engl J Med. 2000 May 4;342(18):1334-49
pubmed: 10793167
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Am J Trop Med Hyg. 1993 Apr;48(4):554-67
pubmed: 8480865
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Curr Opin Allergy Clin Immunol. 2003 Dec;3(6):467-73
pubmed: 14612671
J Pathol. 2003 Jul;200(3):282-9
pubmed: 12845623
JAMA Intern Med. 2020 Mar 13;:
pubmed: 32167524
Nat Rev Immunol. 2009 Jul;9(7):465-79
pubmed: 19521399
Infect Genet Evol. 2018 Jul;61:183-184
pubmed: 29625240
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Immunotherapy. 2016 Jul;8(8):959-70
pubmed: 27381687
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
FEBS J. 2014 Oct;281(20):4568-82
pubmed: 25154302
Lab Invest. 1989 Sep;61(3):319-22
pubmed: 2788773
Malar Res Treat. 2014;2014:625905
pubmed: 24575311
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Semin Immunopathol. 2017 Jul;39(5):517-528
pubmed: 28555385
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Nature. 2014 Oct 16;514(7522):372-375
pubmed: 25119032
Annu Rev Virol. 2015 Nov;2(1):95-117
pubmed: 26958908
Nature. 2009 Mar 26;458(7237):514-8
pubmed: 19158675
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
J Virol. 2005 Aug;79(15):10083-7
pubmed: 16014971
mBio. 2012 Nov 20;3(6):
pubmed: 23170002
Clin Rev Allergy Immunol. 2014 Oct;47(2):234-43
pubmed: 25086642
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
J Vasc Interv Radiol. 2001 Jun;12(6):677-82
pubmed: 11389218
Ann N Y Acad Sci. 2001;936:276-90
pubmed: 11460484
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet. 2003 May 24;361(9371):1773-8
pubmed: 12781536
Oncogene. 2001 Oct 1;20(44):6473-81
pubmed: 11607846
Front Biosci. 2005 Sep 01;10:2504-17
pubmed: 15970513
Immunity. 2012 Jan 27;36(1):32-42
pubmed: 22265677
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
Pediatr Infect Dis J. 2007 Aug;26(8):753-5
pubmed: 17848893
Pediatrics. 2007 Jan;119(1):e70-6
pubmed: 17130280

Auteurs

Jyoti Upadhyay (J)

School of Health Sciences, University of Petroleum and Energy Studies, Dehradun 248197, India.

Nidhi Tiwari (N)

Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation, Delhi 110054, India.
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147002, India.

Mohd N Ansari (MN)

Department of Pharmacology & Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH